# A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07361003/  
OnCo record `nct07361003` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trifluridine/tipiracil in colorectal cancer, run by Jiangsu Simcere Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07361003 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 464 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-01. Interventions recorded: Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07361003
- Phase: 3
- Setting: A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer
- Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Enrolled: 464

## Sources

- ClinicalTrials.gov NCT07361003: https://clinicaltrials.gov/study/NCT07361003

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Simcere Pharmaceutical](https://onco.cc/companies/simcere/)

---
JSON: https://onco.cc/api/v1/entities/nct07361003.json